We are live on ! Find out more
ALBO

Albireo Pharma Inc
ALBO

Delisted

ALBO was delisted on the 2nd of March, 2023.

Back to rankings

1 hedge funds and large institutions have $756 invested in Albireo Pharma Inc in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less funds holding

Funds holding: 3 → 1 (-2)

100% less capital invested

Capital invested by funds: $2.04M → $756 (-$2.04M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale
Germany
-$1.99M
2
GKIM
GW&K Investment Management
Massachusetts
-$48K
Name Holding Trade Value Shares
Change 		Change in
Stake
HNB
1
Huntington National Bank
Ohio
$756 – – –
DekaBank Deutsche Girozentrale
2
DekaBank Deutsche Girozentrale
Germany
– -$1.99M -45,000 Closed
GKIM
3
GW&K Investment Management
Massachusetts
– -$48K -1,080 Closed

ALBO Hedge Fund Activity: Q2 2023 in Review

1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Albireo Pharma Inc (ALBO) for Q2 2023, worth a combined $756 — down 100% from $2.04M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ALBO and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $1.99M sold.

  • 1 institutional investor held Albireo Pharma Inc (ALBO) as of Q2 2023, down from 3 in Q1 2023.
  • Funds reported $756 of Albireo Pharma Inc stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Albireo Pharma Inc positions in Q2 2023 and 2 closed out, a net change of -2 holders.
  • The largest Albireo Pharma Inc seller in Q2 2023 was DekaBank Deutsche Girozentrale, an estimated $1.99M sold.

Based on aggregated 13F filings for Q2 2023.